Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus temozolomide for recurrent glioma
ChiCTR1800020145Phase 4Completed
- Sponsor
- Beijing Sanbo Brain Hospital
- Start
- Oct 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and temozolomide in glioma, sponsored by Beijing Sanbo Brain Hospital. Primary endpoint: 6-month progression-free survival rate. Started Oct 2015; status: completed.
02
Drugs
Rivoceranibtemozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR1800020145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020145.